Archer advances quantum and biochip tech despite wider full-year loss

Archer Materials Limited reported a net loss of $6,972,006 for the year ended June 30, 2025, an increase from $4,803,150 in the prior year. Key expenditures included $4,791,577 on quantum and biochip technology research and $1,889,842 in share-based payments. Despite the loss, the company maintains a strong cash position of $13,744,700, reflecting a decrease from $18,209,820 in 2024 due to direct expenditures on research and intellectual property.

Technological advancements include improved control capabilities and increased spin coherence times for its 12CQ quantum project, with the development of a new resonator circuit and proof-of-concept superconducting circuits. In bioelectronics, Archer integrated its biosensor with CMOS readout circuitry, identified chronic kidney disease as a first use case, and miniaturized its biosensor chip design, significantly reducing its size and cost.

Strategic developments include the appointment of Dr. Simon Ruffell as chief executive in March 2025 and the establishment of an Advisory Committee. The company's patent portfolio expanded with new applications in quantum and biochip technologies, reinforcing its intellectual property strategy and commitment to commercialisation.